Literature DB >> 8445678

13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix.

S M Lippman1, J J Kavanagh, M Paredes-Espinoza, F Delgadillo-Madrueño, P Paredes-Casillas, W K Hong, G Massimini, E E Holdener, I H Krakoff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8445678     DOI： 10.1093/jnci/85.6.499

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  13 in total

Review 1.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

Review 2.  Differentiating agents in pediatric malignancies: retinoids in neuroblastoma.

Authors:  C P Reynolds
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

3.  Unexpected radiation protection with 13-cis-retinoic acid plus interferon alpha-2a.

Authors:  K A Mason; P J Tofilon
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Peroxisome proliferator-activated receptor gamma overexpression suppresses growth and induces apoptosis in human multiple myeloma cells.

Authors:  Tatiana M Garcia-Bates; Steven H Bernstein; Richard P Phipps
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

Review 5.  GRIM-19: A master regulator of cytokine induced tumor suppression, metastasis and energy metabolism.

Authors:  Shreeram C Nallar; Dhan V Kalvakolanu
Journal:  Cytokine Growth Factor Rev       Date:  2016-09-15       Impact factor: 7.638

6.  Combination of highly purified human leukocyte interferon alpha and 13-cis-retinoic acid for the treatment of metastatic melanoma.

Authors:  G Fierlbeck; T Schreiner; G Rassner
Journal:  Cancer Immunol Immunother       Date:  1995-03       Impact factor: 6.968

7.  Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer.

Authors:  Mihae Song; Robert S DiPaola; Bernadette M Cracchiolo; Darlene G Gibbon; Mira Hellmann; Wilberto Nieves-Neira; Ami Vaidya; Allison R Wagreich; Weichung J Shih; Lorna Rodriguez-Rodriguez
Journal:  Int J Gynecol Cancer       Date:  2014-11       Impact factor: 3.437

8.  Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial.

Authors:  Thehang Luu; Paul Frankel; Jan H Beumer; Dean Lim; Mihaela Cristea; Leonard J Appleman; Heinz J Lenz; David R Gandara; Brian F Kiesel; Richard L Piekarz; Edward M Newman
Journal:  Cancer Chemother Pharmacol       Date:  2019-09-14       Impact factor: 3.333

9.  In vivo modulation of several anticancer agents by beta-carotene.

Authors:  B A Teicher; J L Schwartz; S A Holden; G Ara; D Northey
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 10.  Epigenetics of cervical cancer. An overview and therapeutic perspectives.

Authors:  Alfonso Dueñas-González; Marcela Lizano; Myrna Candelaria; Lucely Cetina; Claudia Arce; Eduardo Cervera
Journal:  Mol Cancer       Date:  2005-10-25       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.